Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of “Moderate Buy” from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $17.6667.

A number of analysts have recently commented on the company. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Barclays lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $18.07 on Friday. The company has a 50 day simple moving average of $16.69 and a two-hundred day simple moving average of $14.42. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of 36.88 and a beta of 1.27. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. Amneal Pharmaceuticals has a 12 month low of $8.01 and a 12 month high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. As a group, analysts predict that Amneal Pharmaceuticals will post 0.92 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Large investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Federated Hermes Inc. raised its stake in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares during the period. Transamerica Financial Advisors LLC lifted its position in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares in the last quarter. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.